Merck EBITDA 2010-2024 | MRK

Merck EBITDA for the quarter ending September 30, 2024 was $5.170B, a 24.92% decline year-over-year.

  • Merck 2023 EBITDA was 6.826B, a 69.24% decline from 2022.
  • Merck 2022 EBITDA was 22.191B, a 35.2% increase from 2021.
  • Merck 2021 EBITDA was 16.413B, a 81.68% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Merck EBITDA 2010-2024 | MRK

  • Merck 2023 EBITDA was 6.826B, a 69.24% decline from 2022.
  • Merck 2022 EBITDA was 22.191B, a 35.2% increase from 2021.
  • Merck 2021 EBITDA was 16.413B, a 81.68% increase from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$692.7B
Novo Nordisk (NVO)$460.6B
Johnson & Johnson (JNJ)$368.4B
AbbVie (ABBV)$294.4B
Novartis AG (NVS)$211.1B
AstraZeneca (AZN)$197.8B
Pfizer (PFE)$142.2B
Sanofi (SNY)$121.8B
Innoviva (INVA)$1.2B